Waist and hip circumferences, height, weight, and body mass index (BMI) were measured. Criteria for lipoatrophy were one or more of the following: loss of fat from the face, arms or legs, prominent veins in the arms and legs, and a thin bottom. Lipohypertrophy was defined by the presence of one or more of the following: an increase in abdominal selleck chemicals perimeter, or breast and/or neck fat deposition. We defined mixed lipodystrophy as occurring when at least one
characteristic of lipoatrophy and one of lipohypertrophy were concomitantly present in a given patient. Lipodystrophy was categorized in accordance with the scale proposed by Carr et al. [18]: nil (0), slight (1), moderate (2) and severe (3). Doubtful cases were excluded. This categorization was used for the face, arms, KU-57788 solubility dmso legs, buttocks, abdomen, neck and breasts. The sum of the values
corresponding to each body area indicated the degree of lipodystrophy: nil (0), slight (1–6), moderate (7–12) and severe (13–18) [17, 18]. In this study we included only moderate and severe cases in order to avoid superposition between groups. These were assessed as previously described [18]. Glucose, total cholesterol, high-density lipoprotein cholesterol (HDLc), low-density lipoprotein cholesterol (LDLc) and triglycerides (TG) were measured using the usual enzymatic methods. Hyperglycaemia, hypertriglyceridaemia, hypercholesterolaemia, low HDLc, high LDLc and hyperinsulinaemia were defined using criteria validated elsewhere [19, 20]. IR was calculated according to the homeostasis model assessment of insulin resistance (HOMA-IR) method [insulin (μIU/mL) × glucose (mmol/L)/22.5] [21]. Resistin, fatty acid binding protein 4 (FABP4) and leptin were
measured using enzyme-linked immunosorbent assays (ELISAs; BioVendor Laboratory Medicine Niclosamide Inc., Palackeho, Czech Republic for resistin and FABP4; Assaypro, St Charles, MO for leptin). Adiponectin levels were measured using a radioimmunoassay kit (Linco Research Inc., St. Charles, MO). Interleukin (IL)-6, soluble tumour necrosis factor receptor 1 (sTNFR1) and serum tumor necrosis factor receptor 2 (sTNFR2) levels were assessed as previously described by our group [13, 22]. These were assessed by ELISA (BioVendor Laboratory Medicine Inc.). The sensitivity was 0.673 ng/mL. The intra- and interassay coefficients of variation (CVs) were < 5% and 6.6%, respectively [11]. Statistical analysis was performed using the spss/pc+ statistical package (version 15; SPSS, Chicago, IL). Prior to the statistical analyses, the data were tested for normal distribution and homogeneity of variances. Normally distributed data are expressed as mean ± standard deviation (SD), whereas variables with a skewed distribution are represented as the median (25th percentile–75th percentile).